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Summary.-Recently developed techniques for the investigation of iron kinetics
were used to study the disturbance of iron metabolism in 19 untreated patients with
Hodgkin's diseases (HD). The erythroid abnormality in newly diagnosed HD appears
to be confined to those patients with systemic symptoms of weight loss, night sweats
and fever, and consists of depression of marrow erythroid activity. These patients
had a significantly lower haemoglobin and serum iron concentration and a higher
serum ferritin concentration, both when compared to normal subjects and to those
patients with HD who lacked systemic symptoms. Ineffective erythropoiesis and red-
cell destruction were not significantly increased. The present findings confirm that
HD patients with systemic symptoms have a depression of erythropoiesis, and that
in these patients the marrow fails to respond to the stimulus of mild anaemia.
THE MECHANISM of anaemia in Hodg-
kin's disease (HD) is unclear. Abnormali-
ties of iron utilization have been noted
on many occasions in the past (Gian-
nopoulos & Bergsagel 1959; Haurani et
al., 1963) and ineffective erythropoiesis
(Cline & Berlin 1963). Beamish et al.
(1972) suggested that impairment of iron
release from the reticuloendothelial (RE)
system with a consequent failure of iron
delivery to the marrow was common in
HD. Many of the patients investigated in
these earlier studies had already under-
gone treatment with radiation and chemo-
therapy. In addition, the ferrokinetic
methods used did not provide a quantita-
tive assessment of effective and ineffective
red-cell production (Cavill & Ricketts,
1974).
The purpose of the preesnt study was to
re-evaluate and define the abnormalities
of iron metabolism and the possible
mechanism ofanaemia in patients present-
ing with HD. Ferrokinetic methods allow-
ing quantitative estimates of erythro-
poiesis were used (Ricketts et al., 1975).
25
PATIENTS
Nineteen newly diagnosed untreated
patients with HD and 14 healthy adults were
studied. Fully informed consent was obtained
in all cases. There were 14 males and 5 female
patients and their ages ranged from 17 to 69
years with a mean of 43 years. None of the
patients was receiving any form of medical
treatment at the time of investigation. The
diagnosis of HD was based on lymphnode
biopsy in all patients, except one in w%hom
the diagnosis xvas made after splenectomy.
Routine haematological and biochemical
investigations, marrow aspiration and tre-
phine biopsy, chest X-ray and hilar tomog-
raphy, radiological skeletal surveyandbipedal
lymphangiography were carried out in all
patients.
The stage ofthe disease was assessed before
laparotomy according to the Ann Arbor
International Convention (Carbone et al.,
1971). All patients except those with biopsy-
proven Stage IV disease then underwent
laparotomy and splenectomy with open liver
biopsy. The histological classification wias
according to Lukes & Butler (1966) as modi-
fied at Rye (Lukes et al., 1966) and Ann Arbor
(Rapport et al., 1971) International Conven-S. AL-ISMAIL ET AL.
tions. The patients were classified as Type A
or B on the basis ofthe absence or presence of
systemic symptoms of unexplained fever
(more than 38°C), wNeight loss of more than
10% during the 6 months preceding the
diagnosis, or night sweats (Carbone et al.,
1971).
AIETHODS
Haemoglobin concentration and inean
corpuscular vollumlle (MCV) w-ere measured
with a Coulter Counter Model S. Serum iron
concentration and total iron-binding capacity
wNere measured according to the method of
Young & Hicks (1965) as modified by Babson
& Kleinmen (1967). The method of Jones &
Worwood (1975) wsas used to measure the
serum ferritin concentration.
Radioisotope studies wAere carried out at
presentation, before laparotomy. A sample
of each subject's plasma transferrin was
specifically labelled Mith 59Fe (Cavill, 1971)
and the plasma 59Fe clearance curve wNas
definied over 10-14 days by the method of
Cavill et atl. (1976). The results wxAere analysed
as described by Ricketts et al. (1975) and the
following parameters wNere calculated: total
erythroid marrow iron turnover (MIT),
effective red-cell iron turnover (RCIT), and
ineffective iron turnover (IIT). The mean cell
lifespan and mean red-cell production were
calculated from red-cell iron turnover. In-
effective iron turnover wNas expressed as a
percentage ofMIT.
Thedifferencesbetweenmeanswiereassessed
using a one-way analysis of variance, wNhilst
correlation between parameters wras assessed
using the Pearson product-moment correla-
tion coefficient.
RESULTS
The number of patients showing dif-
ferent stages of the disease, histological
classes and the presence or absence of
symptoms is shown in Table I. The
haematological and iron status of the
subjects are summarized in Table II. Only
5 of the patients were anaemic (haemo-
globin concentration <13 g/dl for men or
< 12 g/dl for women) but 9 patients
showed a microcytic blood picture (MCV
< 84 fl). There was no significant difference
in the haemoglobin concentration or MCV
between the 4 stages ofthe disease, nor did
TABLE I. The distribution of 19 untreated
patients w(*ith Hodgkin's disease (HD) in
relation to syMpto0mP,s, staye of disease and
histological class8fication
Histological
type
Lymphocytic
pre(lominaiit
Noduilar
sclerosing
M\lixed
celluilarityv
Lymphocyte
(leplete(l
Type A
Type B
Stage of (lisease
I 11 TTI I V
2 1
2 1 4
. _ 4
6 2 4
4 2
they differ from the control group. How-
ever, patients with systemic symptoms
had lower haemoglobin concentrations and
lower MCVs compared both to the normal
subjects and to the patients without such
symptoms (P < 0.005).
There was a significant correlation
between MCV' and serutm iron concentra-
tion (r=0 58, P)< 001) and sideropenia
was predominantly associated with the
presence of systemic symptoms (Table
III). Patients with systemic symptoms
had a mean serum iron concentration
wlhich was significantly lower (P<00005)
than both that of the patients without
such symptoms and that of the normal
group. Although serum iron varied be-
tween the 4 stages of the disease, there
was no clear relationship with advancing
stage. Serum ferritin was significantly
higher in the patients with HD than in the
control group, and significantly higher
concentrations (P < 0 01) were found with
advancing stages of the disease (Table
III). There was a significant negative
correlation between the serum iron con-
centration and serum ferritin concentra-
tion (r= -057, P < 0 02); patients with
low serum iron concentrations had high
ferritin concentrations. This appears to
be related both to the presence ofanaemia
and systemic symptoms. The mean serum
ferritin concentration in the non-anaemic
patients was 185 (Lg/l and the mean value
in the anaemic patients was 776 Mug/l
(P < 0.01); the mean serum ferritin con-
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centration in patients with systemic
symptoms was 795 Htg/l and in those
without such symptoms 122 itg/l (P <
0.005). The serum ferritin in Type A
patients was not significantly different
from normal.
The mean values for marrow iron turn-
over, red-cell iron turnover, ineffective
erythropoiesis and red cell lifespan and
tissue iron turnover are summarized in
Table III. Total MIT and RCIT at each
stage of the disease were similar, and not
significantly different from normal (P>
0.05). Neither the percentage of IIT nor
the red-cell lifespan differed between each
stage of the disease and normal. However,
patients with systemic symptoms had a
lower mean MIT and RCIT than both
normal subjects and Type A patients
(P < 0 01), whereas there were no differen-
ces between patients without symptoms
and normal subjects (Table III). This
correlation of depressed erythropoiesis
and systemic symptoms was particularly
evident in patients with Stage III disease.
The 4 patients with systemic symptoms
Type B had significantly lower MIT
(P < 0 05) and RCIT (P < 0 01) than the
4 T'ype A patients.
DISCUSSION
The principal mechanisms proposed to
account for anaemia in HD are haemolysis
and abnormalities in utilization of iron for
erythropoiesis, characterized by ineffective
erythropoiesis (Cline & Berlin, 1963) and a
reticuloendothelial block in iron release
(Beamish et al., 1972). Zarabi et al. (1977)
have suggested that relative failure of
erythropoiesis rather than an RE block
may be primarily responsible for the
anaemia of chronic disease. The extent to
which these factors contribute to the
anaemia in HD is difficult to assess, be-
cause most studies have been carried out
on patients with advanced disease, many
of whom had already been treated. In a
study of 23 untreated patients with HID
at presentation Beamish et al. (1972) found
that the disturbance in iron metabolism
and erythropoiesis was related to the stage
of the disease. However, the staging and
the division of patients into those with
localized and generalized disease was based
on clinical observation only. Whittaker
et al. (1978) found that 24/60 patients
(400%) changed their clinical stage after
laparotomy and splenectomy. This em-
phasizes the importance of laparotomy
and splenectomy in disease staging and in
relating the stage of the disease to the
disturbance of iron metabolism.
A reduced serum iron concentration in
the presence of stainable iron in the mar-
row is characteristic of the anaemia of
HD, and serum iron concentration was
significantly lower than normal in our
patients. However, no coiisistent decrease
in the level of serum iron with advaincing
pathological stage was observed. The most
striking difference in serum iron concentra-
tion was between the low levels in patients
with systemic symptoms and the levels in
symptom-free patients. Five ofourpatients
showed ahypochromic microcytic anaemia.
Ultmann et al. (1966) found such anaemia
in 10% of patients with HD at presenta-
tion. None of our patients haad iron
deficiency as judged from stainable iron
in the marrow or the level ofserum ferritin.
The latter was higher than in the normal
subjects, and increasing concentrations
were found with advancing stages of the
disease. Significantly higher eoncentra-
tions were found in patients withl systemic
symptoms. These were similar to those
of Jones et al. (1973) and Jacobs et al.
(1976), who showed that the increased
serum ferritin concentration was related
to the activity and spread of HD. The
increased serum ferritin concentration in
HD are probably related partly to anaemia
and partly to the nonspecific and poorly
understood changes known to occur in RE
cells of all cancer patients (Cartwrigbt &
Lee, 1971). Liver involvement may be a
factor contributing to high serum ferritin
in Stage IV disease.
Red-cell lifespan was not significantly
reduced in our patients. Two of 8 un-
treated patients with HD described by
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Beamish et al. (1972) had a shortened red-
cell lifespan as measured by 51Cr. How-
ever, in generalized disease, haemolysis
seemed to be more common, and occurred
in 70-90% of patients (Ultmann, 1958;
Najean et al., 1967; Cline & Berlin, 1963;
Giannopoulos & Bergsagel, 1959). In-
effective erythropoiesis has been suggested
as a possible mechanism contributing to
the anaemia of HD (Cline & Berlin, 1963),
although this could only be inferred from
the data at that time. Measurement of
ineffective erythropoiesis in our patients
showed this to be at normal levels. The
most striking erythroid abnormality in our
patients was a depression oftotal marrow-
iron turnover and conisequently ofeffective
red-cell iron turnover in those patients
with systemic symptorns. This association
of systemic symptoms with depressed
erythropoiesis was seen in patients who
share the same pathological stage of the
disease. In the 8 patients in Stage III,
MIT aind RCIT were lower in the 4 patients
with Type B disease.
Our results suggest that an abnormality
of erythropoiesis is not necessarily linked
directly to an abnormality ofiron metabol-
ism. Zarabi et al. (1977), using an animal
model, suggested that relative failure of
erythropoiesis may be primarily respon-
sible for the anaemia of chronic disease,
and our results are consistent with this
hypothesis. The cause of this depression
remains unclear however. Ward et al.
(1971) reported a decrease in plasma
erythropoietin levels in patients with
lymphoma, as well as in patients with
chronic inflammation andinfection. Zucker
et at. (1974), however, found that serum
erythropoietin levels are elevated in the
anaemia of malignancy but elicit a de-
creased marrow response. The production
of catabolic tumour products, the secretion
of physiological inhibitors of erythro-
poiesis, or some form of metabolic com-
petition, have been previously postulated
as possible causes of failure of marrow
response (Bowdler & Prankered, 1962;
Field et atl., 1968). The association of
systemic symptoms and marrow depres-
sion in our patients may suggest a com-
mon pathophysiological mechanism of
both phenomena, but evidence on the
pathogenesis of erythroid suppression is
lacking at present.
S.A.I. was a Leukaemia Researclh Fund Clinical
Research Fellow.
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